The firm is a Europe-based venture capital investor focused exclusively on therapeutics, with an investment team spanning Europe, North America, and the Middle East. The firm typically makes several new investments annually and invests from Seed through Series B, with commitments of up to approximately $5M–$6M per company. The firm is flexible regarding financing structures and considers traditional equity investments, SAFEs, and convertible notes. The firm can co-lead financing rounds or participate in investment syndicates. The firm invests globally, with significant investment activity in North America.
The firm invests exclusively in therapeutics and has a particular preference for advanced therapeutic modalities, especially genetic medicines. The firm is broadly indication-agnostic and considers a wide range of therapeutic approaches on a case-by-case basis. The firm focuses on preclinical-stage companies developing differentiated therapeutic technologies with strong scientific foundations and the potential to address meaningful unmet medical needs. While advanced modalities represent a priority, the firm remains open to other therapeutic technologies demonstrating compelling scientific and commercial potential.
From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition or prior entrepreneurial experience. The firm seeks companies developing differentiated therapeutic programs with credible scientific rationale and opportunities for significant value creation. The firm is comfortable participating alongside other investors and may take a co-lead role depending on the financing opportunity.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
